Date: 2011-02-22
Type of information: R&D agreement
Compound: protein biomarkers
Company: Pronota (Belgium) Molecuence Corporation (Japan)
Therapeutic area: Cerebrovascular diseases
Type agreement: R&D
Action mechanism:
Disease: stroke
Details: Pronota NV has entered into an agreement with Molecuence Corporation (wholly owned subsidiary of Mitsubishi Chemical Corporation), to discover and validate protein biomarkers in stroke. Pronota will apply its proven proprietary platforms for protein biomarker discovery (MASStermind®) and biomarker verification (MASSterclass™) to this project.
Financial terms: Financial details were not disclosed.
Latest news:
